Clinical resource
Head and neck nasopharynx definitive EBRT chemoradiation (eviQ ID 621)
eviQ, Cancer Institute NSW
DoseLab summary
Endorsed eviQ protocol for definitive chemoradiation of nasopharyngeal carcinoma (T2 or higher, any N). It summarizes the 2025 primary and nodal target delineation guidelines and notes where the 2024 international guideline differs. Separate eviQ protocols cover early-stage disease and chemoradiation after induction chemotherapy.
Why this is useful
Definitive chemoradiation for nasopharyngeal carcinoma, summarizing the 2025 target delineation guidelines and the NPC-specific organ limits.
Reference details
- Title
- Head and neck nasopharynx definitive EBRT chemoradiation (eviQ ID 621)
- Authors / organization
- eviQ, Cancer Institute NSW
- Publication / protocol
- eviQ Radiation Oncology protocol 621
- Version
- v.6 — last reviewed 30 April 2026; review due 30 June 2030
- Year
- 2026
- DOI
- Pending verification
- Disease sites
- Head & Neck
- Topics
- Head & Neck, Dose Constraints, Protocols
- Fractionation context
- 70 Gy / 35 fx SIB (60 and 50 Gy dose levels); alternatives in 33–35 fx
- Last reviewed by DoseLab
- 2026-09-24